Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2411 • ACR Convergence 2024
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Arushi Ramnarain¹, Xiaomeng Xu², Joanna Kent³, Sagar Jagtiani⁴, Worawit Louthrenoo⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yi-Hsing Chen⁸, Jiacai Cho⁹, Chiu Wai Shirley Chan¹⁰, Sandra Navarra¹¹, Haihong Yao¹², Lydia Pok¹³, BMDB Basnayake¹⁴, Zhuoli Zhang¹⁵, Madelynn Chan¹⁶, Sang-Cheol Bae¹⁷, Yasuhiro Katsumata¹⁸, Jun Kikuchi¹⁹, Sean O'Neill²⁰, Fiona Goldblatt²¹, Yih Jia Poh²², Mark Sapsford²³, Nicola Tugnet²⁴, Kristine Pek Ling Ng²⁵, Cherica Tee²⁶, Yoshiya Tanaka²⁷, Mandana Nikpour²⁸, Alberta Hoi²⁹, Eric Morand³⁰ and Rangi Kandane-Rathnayake³¹, ¹Monash Health, Melbourne, Victoria, Australia, ²GSK, Value, Evidence & Outcomes, Singapore, Singapore, ³Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, ⁴Glaxo Smith Kline, Singapore, Singapore, ⁵Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ⁹National University Hospital, Singapore, Singapore, ¹⁰Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹¹University of Santo Tomas, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, ¹³University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, ¹⁴Teaching Hospital, Kandy, Sri Lanka, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁹Keio University School of Medicine, Tokyo, Japan, ²⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²SingHealth, Singapore, Singapore, ²³WDHB, Auckland, New Zealand, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Health New Zealand, Auckland, New Zealand, ²⁶Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, ²⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸The University of Sydney, Melbourne, Victoria, Australia, ²⁹Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ³⁰School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ³¹Monash University, Clayton, Victoria, Australia
Background/Purpose: LN is prevalent in SLE, occurring in up to 50% of patients. Treatment response is evaluated by improvement in proteinuria and renal function, and…
Abstract Number: 2427 • ACR Convergence 2024
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus
Ioanna Minopoulou¹, Olaf Penack², Fredrik Albach¹, Artur Wilhelm³, Arnd Kleyer⁴, Dominic Borie⁵, Vincent Casteleyn¹, Robert Biesen¹, Philipp Enghard⁶, Thomas Dörner⁷, Norman Drzeniek⁸, Jan Zernicke¹, Tobias Alexander³, Kamran Movassaghi², Marie Luise Hütter-Krönke⁹, Eva Schrezenmeier⁶, Adrian Schreiber¹⁰, udo schneider¹, Lars Bullinger¹¹, Gerhard Krönke¹² and David Simon¹³, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/ Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Kyverna Therapeutics, Inc., Emeryville, CA, ⁶Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany/ Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany/Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Berlin, Germany, Berlin, Germany, ⁹Department of Hematology, Oncology and Cancer Immunology, Charité University Medicine Berlin, Campus Steglitz, Berlin, Germany, Berlin, Germany, ¹⁰Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany, Berlin, Germany, ¹¹Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany/ Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, Berlin, Germany, ¹²Rheumatology, Charité, Berlin, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic option for treatment-refractory patients with B cell-mediated diseases such as systemic…
Abstract Number: 2555 • ACR Convergence 2024
Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus
Shivani Garg¹, Jay Patel¹, Meredith Ingersoll², Shelby Gomez², Amanda Weber², Sarah Panzer¹, Sancia Ferguson³, Tripti Singh¹ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²UW Health, Madison, ³University of Wisconsin, Madison, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: A complex interaction between biologic factors and social determinants of health (SDoH) drives disparities in lupus (or SLE) outcomes in the US. A recent…
Abstract Number: 2623 • ACR Convergence 2024
Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Kaveh Ardalan¹, Angel Davalos², Hwanhee Hong², Bryce Reeve², Christoph Hornik², M. Athony Moody², Donald Lloyd-Jones³, Eveline Wu⁴, Audrey Ward¹, Rebecca Sadun⁵, Jeff Dvergsten⁶, Ann Reed², Mark Connelly⁷ and Laura Schanberg⁸, ¹Duke University School of Medicine, Durham, NC, ²Duke University School of Medicine, Durham, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴University of North Carolina School of Medicine, Chapel Hill, NC, ⁵Duke University, Durham, NC, ⁶Duke University Hospital, Hillsborough, NC, ⁷Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, ⁸Duke University Medical Center, DURHAM, NC
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…
Abstract Number: 0002 • ACR Convergence 2024
Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
Byeong Hyeok Choi¹, Vincent M DeStefano², Masayuki Wada², Kevin G Pinz¹, Greg Deener², Nabil Hagag¹, Ahmed Abdel-Razek¹, Yu Ma³, Jing Luo³ and Yupo Ma², ¹iCell Gene Therapeutics Inc., Stony Brook, NY, ²iCell Gene Therapeutics, Inc., Stony Brook, NY, ³iCar Bio Therapeutics Ltd, Zhongshan City, Guangdong, China (People's Republic)
Background/Purpose: CD19 single and BCMA-CD19 compound chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable activity against autoimmune disorders, although relapses with CD19 CAR…
Abstract Number: 0096 • ACR Convergence 2024
Simultaneous Contribution of Brain-Intrinsic and Peripheral Disease Mechanisms to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus (NPSLE)
Hadijat Makinde¹, Mohammad Khan¹, Cecilia Stumpf², Yidan Wang³, Tyler Therron², Margaret Goldman², Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Hanover Park, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: While NPSLE are among the least understood complications, increasing evidence points to microglia, a brain-resident innate immune cell population, as a driver of disease.…
Abstract Number: 0171 • ACR Convergence 2024
Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, JoonSuk Park², Kamil Barbour³, Kurt Greenlund³, Maria Dall'Era⁴ and Jinoos Yazdany², ¹UCSF, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³CDC, Alpharetta, GA, ⁴UCSF, Corte Madera, CA
Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1 Among Asian adults in the general US population, discrimination has been…
Abstract Number: 0196 • ACR Convergence 2024
Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Zoe Reed¹, Xana Howard¹, Cristina Arriens¹, Teresa Aberle¹, Wade DeJager², Joan Merrill³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity…
Abstract Number: 0373 • ACR Convergence 2024
Enhancing Lupus Patient Education and Support at Kings County Hospital
Dmytro Gatsak¹, Jayashree Gandhi¹, Aleksander Feoktistov², Eugeniya Golub³ and Michael Trevisonno⁴, ¹Kings County Hospital/ SUNY Downstate Medical Center, Brooklyn, NY, ²Kings County Hospital Center/ H+H NYC, Brooklyn, NY, ³Kings County Hospital/ SUNY Downstate Medical Center, Staten Island, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Kings County Hospital, located in Brooklyn, New York, sees an estimated 243 patients with Systemic Lupus Erythematosus (SLE) annually. The patient demographic is predominantly…
Abstract Number: 0454 • ACR Convergence 2024
Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System
Alana Haussmann¹, Eunice Adu Dapaah², John FitzGerald² and Maureen McMahon³, ¹University of California Los Angeles, Santa Monica, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Prior research has outlined an increased incidence of cervical dysplasia and cervical cancer in women diagnosed with systemic lupus erythematosus (SLE). These individuals face…
Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Megan Clowse¹, Kateena Addae-Konadu², Jerome Federspiel³, Jennifer Gilner², Andra James², Eugene Kovalik², Anika Lucas³, Laura Neil², Catherine Sims⁴, Amanda Snyderman², Samir Soneji² and Amanda Eudy⁵, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…
Abstract Number: 0909 • ACR Convergence 2024
Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics
Aleksandra Bylinska¹, Miles Smith¹, Rufei Lu¹, Benjamin Jones², Carla Guthridge¹, Matthew Caleb Marlin¹, Christian Wright³, Susan Macwana³, Wade DeJager³, Marci Beel³, Christopher Lessard¹, Cristina Arriens¹, Joan Merrill⁴, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].